Jared Moskowitz
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsJared Moskowitz bought $15,001 - $50,000 in $GS (Goldman Sachs Group, Inc.) on 2025-10-10, 25 days before the Merchant Banking Modernization Act (HR5291) was introduced, a bill that could benefit financial holding companies.
Jared Moskowitz sold $1,001 - $15,000 in $JNJ (Johnson & Johnson Common Stock) on 2025-10-10, 41 days before the Lowering Drug Costs for American Families Act (HR6166) was introduced, a bill that could impact pharmaceutical company revenues.
Jared Moskowitz bought $1,001 - $15,000 in $MCK (McKesson Corporation Common Stock) on 2025-10-10, 41 days before the Baby Bonus Act (HR6234) was introduced, which could increase disposable income for families.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $AXP | American Express Company Common Stock (AXP) [ST] | $15K-$50K | $316.26 | — | — | Oct 10, 2025 |
| BUY | $AVGO | Broadcom Inc. - Common Stock (AVGO) [ST] | $15K-$50K | $324.63 | — | — | Oct 10, 2025 |
| BUY | $CSCO | Cisco Systems, Inc. - Common Stock (CSCO) [ST] | $15K-$50K | — | — | — | Oct 10, 2025 |
| BUY | $DELL | Dell Technologies Inc. Class C Common Stock (DELL) [ST] | $15K-$50K | $150.57 | — | — | Oct 10, 2025 |
| BUY | $GS | Goldman Sachs Group, Inc. (GS) [ST] | $15K-$50K | $764.36 | — | — | Oct 10, 2025 |
| BUY | $AXP | American Express Company Common Stock (AXP) [ST] | $1K-$15K | $316.26 | — | — | Oct 10, 2025 |
| BUY | $AXP | American Express Company Common Stock (AXP) [ST] | $1K-$15K | $316.26 | — | — | Oct 10, 2025 |
| BUY | $AVGO | Broadcom Inc. - Common Stock (AVGO) [ST] | $1K-$15K | $324.63 | — | — | Oct 10, 2025 |
| BUY | $AVGO | Broadcom Inc. - Common Stock (AVGO) [ST] | $1K-$15K | $324.63 | — | — | Oct 10, 2025 |
| BUY | $CSCO | Cisco Systems, Inc. - Common Stock (CSCO) [ST] | $1K-$15K | — | — | — | Oct 10, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Lowering Drug Costs for American Families Act
The Lowering Drug Costs for American Families Act (HR6166) expands Medicare drug negotiation from 20 to 50 drugs and extends inflation rebates to commercial markets, targeting bearish revenue compression for major pharma ($MRK, $PFE, $LLY). Health insurers ($UNH, $CVS) face mixed effects — lower drug costs offset by new out-of-pocket caps. The bill is in early committee stage, giving markets time to price in the structural shift.
Skinny Labels, Big Savings Act
HR6485 (Skinny Labels, Big Savings Act) creates a statutory safe harbor protecting generic and biosimilar manufacturers from patent infringement liability when marketing drugs for non-patented indications, directly reversing the GlaxoSmithKline v. Teva precedent. Generic makers TEVA and VTRS are structural winners, with reduced litigation risk supporting their generic launch strategies. Brand-name manufacturers AMGN, PFE, JNJ, and MRK face accelerated competitive erosion on their top-selling drugs. The bill is early-stage (referred to House Judiciary), but companion Senate bill S43 signals bipartisan interest.
Baby Bonus Act
The Baby Bonus Act (HR6234) has been stuck in the House Ways and Means Committee for over five months with no appropriations and no cosponsors from committee leadership. It has zero current or near-term market impact. No tickers meet confidence thresholds for inclusion.
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.
HR5917 is an early-stage procedural bill authorizing the President to extend normal trade relations to most countries by waiving the Jackson-Vanik amendment. It authorizes no funding and changes no current tariff levels. Real market data shows $WMT at $130.81 near its 52-week high, with a 30-day gain of 5.25%, and $AAPL up 8.8% in 30 days—indicating that favorable trade expectations are already priced in. The bill faces a long legislative path with no near-term market impact.
Improving SBA Engagement on Employee Ownership Act
HR5778, the Improving SBA Engagement on Employee Ownership Act, passed the House with unanimous committee support and is now on the Union Calendar. The bill mandates the SBA to actively participate in federal employee ownership working groups and dedicate a specific program to ESOP outreach. This is a low-cost procedural win for ESOP-focused financial institutions, with no new appropriated funding but a clear structural catalyst for ESOP transaction volume. Major banks with ESOP lending and advisory operations—JPMorgan, Bank of America, and Wells Fargo—are the primary beneficiaries.
SUPPORT for Patients and Communities Reauthorization Act of 2025
The SUPPORT for Patients and Communities Reauthorization Act (P.L. 119-44) became law on December 1, 2025, extending federal substance use disorder and mental health funding through FY2030. This creates a structural tailwind for diagnostic testing (LH, DGX) and pharmaceutical distribution (CAH) via sustained grant programs, while also providing a positive policy backdrop for psychedelic therapy developers (CMPS, MNMD). Recent market data shows diagnostic stocks declining over the past 30 days, with LH at $261.79 (-1.88% 30d) and DGX at $193.52 (-1.26% 30d), suggesting the market has not yet priced in this long-term authorization catalyst.
ROBINHOOD Act
The ROBINHOOD Act (HR6438) in early-stage committee referral imposes a 20% excise tax on securities-based lending for high-income borrowers, directly threatening a key wealth management revenue stream at Goldman Sachs, Morgan Stanley, and JPMorgan. Current market data shows no price impact from this bill yet — GS at $920.37 (-0.71% 7-day), MS at $188.86 (+0.42% 7-day), JPM at $312.85 (+1.48% 7-day) — as the legislative path is long. But structural risk is real: this product is a sticky, high-margin relationship anchor for wealth management franchises.
Stop Stealing our Chips Act
Stop Stealing our Chips Act (HR6322) establishes a whistleblower program for export control violations on advanced AI chips but allocates no new funding and imposes no new restrictions. Compliance costs increase marginally for affected chip exporters, with no immediate financial gains or losses for major semiconductor companies.
Affordable Housing Bond Enhancement Act
The Affordable Housing Bond Enhancement Act (S1511) would expand mortgage revenue bond programs, lowering financing costs for first-time and moderate-income homebuyers. Entry-level homebuilders ($DHI, $LEN, $PHM, $KBH) are structurally positioned to benefit from increased buyer demand, while major bond underwriters ($BAC, $JPM, $WFC) could see modest fee increases from higher issuance volumes. The bill is early-stage (post-hearing in Senate Banking Committee, companion in House Ways and Means) with no appropriations — it changes tax code provisions, not direct spending.
Merchant Banking Modernization Act
The Merchant Banking Modernization Act (HR5291) extends the holding period for merchant banking investments from 10 to 15 years for financial holding companies. The bill is active and on the Union Calendar after passing committee with a 35-17 vote. This is a direct regulatory benefit for large banks engaged in private equity and merchant banking, particularly Goldman Sachs and Morgan Stanley, whose merchant banking divisions are core profit centers. The bill carries no direct federal spending — it is a regulatory change, not an appropriation.
Other Filings by Jared Moskowitz
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.